EOLS Q1 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$59M+42.2% YoY

Gross Profit

$41M68.3% margin

Operating Income

-$9M-15.0% margin

Net Income

-$13M-22.1% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-2.7%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$226M

Total Liabilities

$208M

Stockholders' Equity

$18M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$42M	+42.2%
Gross Profit	$41M	$30M	+37.0%
Operating Income	-$9M	-$12M	+25.9%
Net Income	-$13M	-$15M	+11.4%

Revenue Segments

Product

$59M99%

Service

$369,0001%